新闻列表

Journey Medical's rosacea drug Emrosi is approved by the FDA

2024-11-06


On November 4, Journey Medical announced that the FDA has approved Emrosi™ (Minocycline hydrochloride sustained release capsule, 40mg) for the treatment of inflammatory lesions in adults with rosacea.

The approval is supported by positive data from two Phase III clinical studies. The subjects completed the 16-week treatment with no significant safety concerns. In both studies, Emrosi significantly outperformed the current standard of treatment, Orace capsules, and placebo, in the Investigator's Global Assessment of treatment success and reduction in the total number of inflammatory lesions.


上一页: Journey Medical红斑痤疮药物Emrosi获FDA批准上市

下一页: 【世界上唯一一个能够预防癌症的疫苗】盘点:国产HPV疫苗崛起!打破垄断,迎接千亿市场新机遇